Julie Green Biography and Net Worth

Chief Human Resources Officer of Invivyd

Julie Green, M.B.A. has served as our Chief Human Resources Officer since January 2024. She joined Invivyd in January 2022 to provide strategic leadership on people matters while directing key initiatives for the Invivyd workforce, and she previously served as our Senior Vice President of Human Resources. Ms. Green also served as our Head of Communications from October 2024 to September 2025. Specializing in fast-paced and high-growth environments, Julie has demonstrated her passion for fostering connections, differentiating the employee experience, and ultimately making a difference for patients and their families during her more than 25 years of human resources experience. Prior to joining Invivyd, she was Vice President of Human Resources at Flexion Therapeutics from 2018 to 2022. From 2012 to 2018, she started and led her own HR consulting firm offering strategic advice and HR solutions to a variety of organizations, specializing in the life science space. She holds an M.B.A. from Babson College and a B.S. in Psychology from Union College.

What is Julie Green's net worth?: The estimated net worth of Julie Green is at least $185.81 thousand as of February 18th, 2026. Ms. Green owns 107,717 shares of Invivyd stock worth more than $185,812 as of April 10th. This net worth approximation does not reflect any other investments that Ms. Green may own. Learn More about Julie Green's net worth.
How do I contact Julie Green?: The corporate mailing address for Ms. Green and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Julie Green's contact information.
Has Julie Green been buying or selling shares of Invivyd?: Julie Green has not been actively trading shares of Invivyd during the past quarter. Most recently, Julie Green sold 20,964 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a transaction totalling $33,123.12. Following the completion of the sale, the insider now directly owns 107,717 shares of the company's stock, valued at $170,192.86. Learn More on Julie Green's trading history.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

Julie Green Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	20,964	$1.58	$33,123.12	107,717
2/17/2026	Sell	19,663	$1.54	$30,281.02	128,681
8/19/2025	Sell	29,643	$0.57	$16,896.51	49,344
8/18/2025	Sell	20,013	$0.65	$13,008.45	78,987

Julie Green Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.77

$1.62

$1.77

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.77

$0.46

$3.07

Volume

8,572,829 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield